Circulating Tumor Cells as a Predictor of Treatment Response in Clinically Localized Prostate Cancer.

ABSTRACT: Using nonenrichment-based, potentially more sensitive Epic Sciences circulating tumor cell (CTC) platform, we sought to detect and characterize CTCs in untreated, high-risk localized prostate cancer and to evaluate their clinical implication. Between 2012 and 2015, blood samples were prospectively collected from patients with National Comprehensive Cancer Network high-risk localized prostate cancer undergoing either radiotherapy (XRT) plus androgen deprivation therapy or radical prostatectomy (RP) with curative intent. Samples were analyzed with the Epic Sciences platform with 4J,6-diamidino-2-phenylindole, CD45, cytokeratin (CK), and androgen receptor (AR) N-terminal staining. CTC counts were correlated with biochemical recurrence (BCR). A diversity of CTC subtypes, including CK-positive,

SUBMITTER: Salami SS 

PROVIDER: S-EPMC7440257 | biostudies-literature | 2019

REPOSITORIES: biostudies-literature